Searchable abstracts of presentations at key conferences in endocrinology

ea0044p137 | Neoplasia, cancer and late effects | SFEBES2016

The effects of proton pump inhibitor therapy on neuroendocrine tumour biomarkers

Constantinou Christoforos , Hill Neil , Bloom Steve , Murphy Kevin , Bech Paul

Introduction: Neuroendocrine tumours (NETs) comprise a heterogeneous group of tumours that constitute a diagnostic and therapeutic challenge. The most commonly used general NET circulating biomarker is Chromogranin A (CgA). CgA is elevated under other circumstances, notably by the use of Proton Pump Inhibitors (PPIs) and possibly via a gastrin-mediated mechanism. Chromogranin B (CgB) and Cocaine- and Amphetamine-Regulated transcript (CART) are two less commonly used NET biomar...